ClinicalTrials.gg
Status unknownNCT04684043POST-PCI FLOWUpdated Feb 26, 2021

Prognostic Implications of Physiologic Investigation After Revascularization With Stent

An observational study in Coronary Disease, sponsored by Bon-Kwon Koo. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-02-26.

Sponsored by Bon-Kwon Koo · Observational

How we know

The sponsor has not verified this record recently (last verified Feb 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
5,100
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Coronary Disease with a site in Korea, Republic of — 6 open to participants now, 7 under way, none of them phase 3. Coronary Disease · Korea, Republic of.

Planned enrollment
3rd of 20
5,100 · median 1,125
Started
2020
the only one that year
Observational
20 of 49
4 open now
Registered
41st of 49
by date
Lead sponsor
2 of 49
Bon-Kwon Koo

Among the 49 studies in Coronary Disease with a site in Korea, Republic of, this one is the 3rd largest by planned enrollment of the 20 observational ones that give a count, is the only one that started in 2020, is one of 20 observational ones, and was the 41st registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

6 of the 49 studies in Coronary Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 20 Years to 100 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Coronary Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Percutaneous coronary intervention (PCI) is a standard treatment strategy for coronary artery disease (CAD). With the presence of myocardial ischemia, PCI reduces the risks of death, myocardial infarction (MI) and revascularization compared to medical therapy. However, the risk of future clinical events remains high, and about 10% of patients experienced further cardiovascular events after PCI. Several factors are associated with these poor outcomes. Well known patient-related risk factors are diabetes mellitus, chronic kidney disease, left ventricular dysfunction, previous MI, and presentation with the acute coronary syndrome. Procedure-related factors, such as stent underexpension, malapposition, edge dissection, the number of the used stent, and total stent length, are also related to poor prognosis after PCI. Recent studies reported that fractional flow reserve (FFR) after coronary stenting, or post PCI FFR, was associated with future clinical outcomes after PCI, and low post PCI FFR value was associated with procedural factors. However, optimal cut-off values of post-PCI FFR ranged widely, from 0.86 to 0.96, and some study reported the limited prognostic value of post-PCI FFR. This might result from differences in study populations, the definition of outcomes, type of stent used, and distribution of included vessels among previous studies.

To establish the clinical relevance of post-PCI FFR and to evaluate the useful cut-off value of post-PCI FFR in daily practice, investigators planned to incorporate all previous evidence of post-PCI FFR by collaboration with international researchers.

Read the detailed description

This study population was incorporated from studies which were already published. Investigators will incorporate all known registries to the POST-PCI FLOW registry by requesting data from principal investigator of each registry.

Investigators will perform systemic review of the previous published data and an updated patient-level meta-analysis of studies, including the most recent publications. PubMed, EMBASE, Cochrane Central Register of Controlled Trials, the United States National Institutes of Health registry of clinical trials, and relevant websites were searched for pertinent published studies. The electronic search strategy was complemented by manual examination of references cited by included articles, recent reviews, editorials, and meta-analyses. No restrictions were imposed on language, study period, or sample size. Searching key words included 'post', 'after', 'PCI', 'Percutaneous coronary intervention', 'coronary stenting', 'stenting', 'stent', 'stent implantation', 'FFR', and 'fractional flow reserve'.

03

Conditions studied

  • Coronary Disease

Keywords

  • fractional flow reserve
  • percutaneous coronary intervention
  • drug-eluting stent
  • coronary atherosclerosis
04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients who were diagnosed as obstructive coronary artery disease and treated by DES and measured post PCI FFR after PCI.

Eligibility criteria

Articles were included when they met the following prespecified criteria: (1) included the patients who underwent PCI with drug-eluting stent (DES); (2) post-PCI FFR was measured after DES implantation; (3) pre-PCI FFR measurement was not mandatory for article inclusion; (4) patients were followed up at least 6 months; (5) clinical outcomes, including all-cause death, cardiac death, target vessel myocardial infarction (TVMI) or target vessel revascularization (TVR), were clearly reported; (6) randomized controlled trials or non-randomized prospective or retrospective registries were included. Two independent investigators screened titles and abstracts, identified duplicated studies, performed full-article reviews, and determined the studies' inclusion. The third investigator supervised the searching process and adjudicated all the disagreements.

  • Patients with \< 2 years.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
5,100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Post PCI state

    The study population of this study underwent percutaneous coronary intervention(PCI) with drug-eluting stent (DES) and measured fractional flow reserve after PCI.

    Device: Percutaneous coronary intervention

Interventions

  • DevicePercutaneous coronary intervention

    PCI was performed using drug-eluting stents

06

What researchers measure

Primary outcomes

  1. Target vessel failure

    A composite of cardiac death, target vessel myocardial infarction and target vessel revascularization

    Time frame: 2 years

Secondary outcomes

  1. Cardiac death or myocardial infarction

    a composite of cardiac death and target vessel myocardial infarction

    Time frame: 2 years

  2. Target vessel myocardial infarction

    Time frame: 2 years

  3. Target vessel revascularization

    Time frame: 2 years

Other outcomes

  1. Cut-off value of post-PCI FFR

    Define the best cut-off value for predicting the future adverse events

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Seoul National University Hospital
    Seoul, Select 03080, Korea, Republic of
    Recruiting
    • Bon-Kwon Koo, MD, PhD · Contactbkkoo@snu.ac.kr · +82-1033561869
    • Seokhun Yang, MD · Contactnewturnz7@gmail.com · +82-1025953470
    • Bon-Kwon Koo, MD, PhD · Principal investigator
08

References and documents

Publications

  • Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/eurheartj/ehy394. No abstract available. Erratum In: Eur Heart J. 2019 Oct 1;40(37):3096. doi: 10.1093/eurheartj/ehz507. PubMed 30165437 ↗
  • Fearon WF, Nishi T, De Bruyne B, Boothroyd DB, Barbato E, Tonino P, Juni P, Pijls NHJ, Hlatky MA; FAME 2 Trial Investigators. Clinical Outcomes and Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease: Three-Year Follow-Up of the FAME 2 Trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation). Circulation. 2018 Jan 30;137(5):480-487. doi: 10.1161/CIRCULATIONAHA.117.031907. Epub 2017 Nov 2. PubMed 29097450 ↗
  • Hwang D, Lee JM, Lee HJ, Kim SH, Nam CW, Hahn JY, Shin ES, Matsuo A, Tanaka N, Matsuo H, Lee SY, Doh JH, Koo BK. Influence of target vessel on prognostic relevance of fractional flow reserve after coronary stenting. EuroIntervention. 2019 Aug 29;15(5):457-464. doi: 10.4244/EIJ-D-18-00913. PubMed 30561367 ↗
  • Li SJ, Ge Z, Kan J, Zhang JJ, Ye F, Kwan TW, Santoso T, Yang S, Sheiban I, Qian XS, Tian NL, Rab TS, Tao L, Chen SL. Cutoff Value and Long-Term Prediction of Clinical Events by FFR Measured Immediately After Implantation of a Drug-Eluting Stent in Patients With Coronary Artery Disease: 1- to 3-Year Results From the DKCRUSH VII Registry Study. JACC Cardiovasc Interv. 2017 May 22;10(10):986-995. doi: 10.1016/j.jcin.2017.02.012. Epub 2017 Apr 26. PubMed 28456699 ↗
  • Rimac G, Fearon WF, De Bruyne B, Ikeno F, Matsuo H, Piroth Z, Costerousse O, Bertrand OF. Clinical value of post-percutaneous coronary intervention fractional flow reserve value: A systematic review and meta-analysis. Am Heart J. 2017 Jan;183:1-9. doi: 10.1016/j.ahj.2016.10.005. Epub 2016 Oct 11. PubMed 27979031 ↗
  • van Zandvoort LJC, Masdjedi K, Witberg K, Ligthart J, Tovar Forero MN, Diletti R, Lemmert ME, Wilschut J, de Jaegere PPT, Boersma E, Zijlstra F, Van Mieghem NM, Daemen J. Explanation of Postprocedural Fractional Flow Reserve Below 0.85. Circ Cardiovasc Interv. 2019 Feb;12(2):e007030. doi: 10.1161/CIRCINTERVENTIONS.118.007030. PubMed 30732469 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2020 (actual). Primary completion is estimated for Feb 2021, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2020
First posted
Dec 24, 2020
StartActual
May 16, 2020
Primary completionEst.
Feb 28, 2021
CompletionEst.
Feb 28, 2021
Last update
Feb 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04684043
Lead sponsor
Bon-Kwon Koo
Collaborators
Inje University Ilsan Paik Hospital, Goyang, South Korea, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, Tsuchiura Kyodo General Hospital, McGovern Medical School at UTHealth and Memorial Hermann Hospital, TX, USA, Nagoya City University Graduate School of Medical Science, Nagoya, Japan, Rutgers Robert Wood Johnson Medical School, Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium, San Raffaele Scientific Institute, Milan, Italy, Ajou University Hospital, Suwon, South Korea, University of Cincinnati, Kyoto Second Red Cross Hospital, Kyoto, Japan, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
Responsible party
Bon-Kwon Koo (Professor, Seoul National University Hospital) — Sponsor-investigator
First posted
Dec 24, 2020
Start date
May 16, 2020
Primary completion
Feb 28, 2021 (estimated)
Completion
Feb 28, 2021 (estimated)
Last update
Feb 26, 2021

Study contacts

Bon-Kwon Koo, MD, PhD
Contact
bkkoo@snu.ac.kr
82-2-2072-2062
Doyeon Hwang, MD
Contact
cardiol.intv@gmail.com
82-10-7446-2779
Bon-Kwon Koo, MD, PhD
study chair · Seoul National University Hospital, Seoul, South Korea
Joon Hyung MD, PhD, MD, PhD
principal investigator · Inje University Ilsan Paik Hospital, Goyang, South Korea
Shao-Liang Chen, MD
principal investigator · Nanjing First Hospital, Nanjing Medical University, Nanjing, China
Tsunekazu Kakuta, MD, PhD
principal investigator · Tsuchiura Kyodo General Hospital
Nils P. Johnson, MD, MS
principal investigator · McGovern Medical School at UTHealth and Memorial Hermann Hospital, TX, USA
Tsuyoshi Ito, MD
principal investigator · Nagoya City University Graduate School of Medical Science, Nagoya, Japan
Abdul Hakeem, MD
principal investigator · Rutgers Robert Wood Johnson Medical School
Bernard De Bruyne, MD, PhD
principal investigator · Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium
Lorenzo Azzalini, MD, PhD
principal investigator · San Raffaele Scientific Institute, Milan, Italy
Hong-Seok Lim, MD, PhD
principal investigator · Ajou University Hospital, Suwon, South Korea
Massoud A. Leesar, MD, PhD, MSc
principal investigator · University of Cincinnati
Akiko Matsuo, MD
principal investigator · Kyoto Second Red Cross Hospital, Kyoto, Japan
Nobuhiro Tanaka, MD, PhD, MSc
principal investigator · Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
Joo Myung Lee, MD, PhD, MSc
principal investigator · Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion